Change in prostaglandin signaling during sickness syndrome hyperalgesia after ovariectomy in female rats

Behav Brain Res. 2021 Jul 23:410:113368. doi: 10.1016/j.bbr.2021.113368. Epub 2021 May 14.

Abstract

The present study investigated hyperalgesia during sickness syndrome in female rats. Hyperalgesia was induced by an intraperitoneal injection of lipopolysaccharide (LPS) or an intracerebroventricular injection of prostaglandin E2 (PGE2). No differences were found in basal mechanical and thermal thresholds or in LPS-induced hyperalgesia in sham-operated animals in the diestrus or proestrus phase or in ovariectomized (OVX) animals. However, higher levels of PGE2 where found in the cerebrospinal fluid of OVX animals compared to sham-operated females. Intracerebroventricular injection of PGE2 produced rapid mechanical hyperalgesia in sham-operated rats while these responses were observed at later times in OVX animals. The protein kinase A (PKA) inhibitor H-89 reduced mechanical PGE2-induced hyperalgesia in OVX female rats, whereas no effect was observed in sham-operated animals. In contrast, the exchange protein activated by cyclic adenosine monophosphate (cAMP; Epac) inhibitor ESI-09 reduced mechanical PGE2-induced hyperalgesia, whereas no effect was observed in OVX animals. PGE2 also induced thermal hyperalgesia in sham-operated and OVX female rats and a similar effect of ESI-09 was observed. These results suggest that PGE2-induced hyperalgesia that is observed during sickness syndrome has different signaling mechanisms in cycling and OVX female rats involving the activation of the cAMP-Epac or cAMP-PKA pathways, respectively.

Keywords: Epac; Hyperalgesia; Prostaglandin; Protein kinase A; Sickness syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cyclic AMP / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors*
  • Dinoprostone / administration & dosage
  • Dinoprostone / pharmacology*
  • Disease Models, Animal
  • Estrous Cycle / drug effects*
  • Female
  • Guanine Nucleotide Exchange Factors / antagonists & inhibitors*
  • Hydrazones / pharmacology
  • Hyperalgesia / chemically induced*
  • Hyperalgesia / drug therapy*
  • Illness Behavior / drug effects*
  • Isoquinolines / pharmacology
  • Isoxazoles / pharmacology
  • Lipopolysaccharides / pharmacology
  • Ovariectomy
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Sulfonamides / pharmacology

Substances

  • 3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile
  • Guanine Nucleotide Exchange Factors
  • Hydrazones
  • Isoquinolines
  • Isoxazoles
  • Lipopolysaccharides
  • Rapgef3 protein, rat
  • Sulfonamides
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Dinoprostone
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide